nach oben

Current Hypertension Reports

30.04.2024 | Hypertension and Emergency Medicine (J Miller, Section Editor)

Considering Adverse Effects of Common Antihypertensive Medications in the ED

verfasst von: Charles R. Wira III, Thomas Kearns, Alex Fleming-Nouri, John D. Tyrrell, Christina M. Wira, Ani Aydin

Erschienen in: Current Hypertension Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To evaluate the adverse effects of common antihypertensive agents utilized or encountered in the Emergency Department.

Recent Findings

All categories of antihypertensive agents may manifest adverse effects, inclusive of adverse drug reactions (ADRs), drug-to-drug interactions, or accidental overdose. Adverse effects, and specifically ADRs, may be stratified into the organ systems affected, might require specific time-sensitive interventions, could pose particular risks to vulnerable populations, and may result in significant morbidity, and potential mortality.

Summary

Adverse effects of common antihypertensive agents may be encountered in the ED, necessitating that ED systems of care are poised to prevent, recognize, and intervene when adverse effects arise.

Sunshine JE, Meo N, Kassebaum NJ, Collison ML, Mokdad AH, Naghavi M. Association of adverse effects of medical treatment with mortality in the United States: a secondary analysis of the global burden of diseases, injuries, and risk factors study. JAMA Netw Open. 2019;2(1):e187041. https://doi.org/10.1001/jamanetworkopen.2018.7041.CrossRefPubMedPubMedCentral

Gahr M, Eller J, Connemann BJ, Schönfeldt-Lecuona C. Subjective reasons for non-reporting of adverse drug reactions in a sample of physicians in outpatient care. Pharmacopsychiatry. 2016;49(2):57–61. https://doi.org/10.1055/s-0035-1569291.CrossRefPubMed

Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96. https://doi.org/10.2165/00002018-200629050-00003.CrossRefPubMed

Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999–2006. Ann Pharmacother. 2012;46(2):169–75. https://doi.org/10.1345/aph.1P592.CrossRefPubMed

Khalil H, Zeltser R. Antihypertensive Medications. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554579/. Accessed 27 June 2023.

American Heart Association, Types of Blood Pressure Medications, Available from: https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications. Accessed 27 June 2023.

Kehrenberg MCA, Bachmann HS. Diuretics: a contemporary pharmacological classification? Naunyn Schmiedebergs Arch Pharmacol. 2022;395(6):619–27. https://doi.org/10.1007/s00210-022-02228-0.CrossRefPubMedPubMedCentral

Goyal A, Cusick AS, Thielemier B. ACE Inhibitors. [Updated 2022 Jul 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430896/. Accessed 27 June 2023.

Triplett JD, Kutlubaev MA, Kermode AG, Hardy T. Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Pract Neurol. 2022;22(3):183–9. https://doi.org/10.1136/practneurol-2021-003194.CrossRefPubMed

10.

Osswald A, Karmonik C, Anderson JR, Rengier F, Karck M, Engelke J, et al. Elevated wall shear stress in aortic type B dissection may relate to retrograde aortic type a dissection: a computational fluid dynamics pilot study. Eur J Vasc Endovasc Surg. 2017;54(3):324–30. https://doi.org/10.1016/j.ejvs.2017.06.012.CrossRefPubMed

11.

Isselbacher EM, Preventza O, Hamilton Black J III, Augoustides JG, Beck AW, Bolen MA, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):e334–482. https://doi.org/10.1161/CIR.0000000000001106.CrossRefPubMed

12.

• Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367. https://doi.org/10.1093/eurheartj/ehaa575. Description: Europeancardiology guidelines.CrossRefPubMed

13.

• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–418. https://doi.org/10.1161/STR.0000000000000211. Description: Acute ischemic stroke guidelines of the ASA/AHA.CrossRefPubMed

14.

• Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282–361. https://doi.org/10.1161/STR.0000000000000407. Description: Intracerebral hemorrhage guidelines from the AHA/ASA.CrossRefPubMed

15.

• Hoh BL, Ko NU, Amin-Hanjani S, Hsiang-Yi Chou S, Cruz-Flores S, Dangayach NS, et al. 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314–70. https://doi.org/10.1161/STR.0000000000000436. Description: Subarachnoid hemorrhage guidelines from th eAHA/ASA.CrossRefPubMed

16.

Masarone D, Martucci ML, Errigo V, Pacileo G. The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis. 2021;8(9):101. https://doi.org/10.3390/jcdd8090101.CrossRefPubMedPubMedCentral

17.

Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. Curr Cardiol Rev. 2015;11(1):53–62. https://doi.org/10.2174/1573403x09666131117174414.CrossRefPubMedPubMedCentral

18.

Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542–52. https://doi.org/10.1016/j.semnephrol.2011.09.009.CrossRefPubMed

19.

Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10–24.CrossRefPubMed

20.

Tomson C, Tomlinson LA. Stopping RAS inhibitors to minimize AKI: more harm than good? Clin J Am Soc Nephrol. 2019;14(4):617–9. https://doi.org/10.2215/CJN.14021118.CrossRefPubMedPubMedCentral

21.

Wright AA, Vesta KS, Stark JE, Smith WJ. Stevens-Johnson syndrome associated with furosemide: a case report. J Pharm Pract. 2010;23(4):367–70. https://doi.org/10.1177/0897190010362260.CrossRefPubMed

22.

James J, Sammour YM, Virata AR, Nordin TA, Dumic I. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to furosemide: case report and review of literature. Am J Case Rep. 2018;19:163–70. https://doi.org/10.12659/ajcr.907464.CrossRefPubMedPubMedCentral

23.

Chaabane A, Fadhl NB, Chadly Z, Fredj NB, Boughattas NA, Aouam K. Captopril-induced DRESS: first reported case confirmed by patch test. Dermatitis. 2013;24(5):255–7. https://doi.org/10.1097/DER.0b013e3182a5d86d.CrossRefPubMed

24.

Vadas P. Hydrochlorothiazide-induced systemic capillary leak. Am J Emerg Med. 2020;38(6):1299.e1-1299.e2. https://doi.org/10.1016/j.ajem.2020.02.029.CrossRefPubMed

25.

Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med. 2012;172(16):1246–51. https://doi.org/10.1001/archinternmed.2012.2754.CrossRefPubMed

26.

Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55. https://doi.org/10.1007/s11906-018-0859-x.CrossRefPubMed

27.

Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens (Greenwich). 2017;19(12):1377–82. https://doi.org/10.1111/jch.13097.CrossRefPubMed

28.

He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490–7. https://doi.org/10.1097/BOR.0000000000000522.CrossRefPubMedPubMedCentral

29.

Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev. 2018;17(9):912–8. https://doi.org/10.1016/j.autrev.2018.03.016.CrossRefPubMed

30.

Reza MJ, Dornfeld L, Goldberg LS. Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus. Arthritis Rheum. 1975;18(4):335–8. https://doi.org/10.1002/art.1780180407.CrossRefPubMed

31.

Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N. ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart J. 2020;72(5):345–50. https://doi.org/10.1016/j.ihj.2020.08.007.CrossRefPubMedPubMedCentral

32.

Yılmaz İ. Angiotensin-converting enzyme inhibitors induce cough. Turk Thorac J. 2019;20:36–42. https://doi.org/10.5152/TurkThoracJ.2018.18014.CrossRefPubMedPubMedCentral

33.

Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β₁-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021;7(1):00801–2020. https://doi.org/10.1183/23120541.00801-2020.CrossRefPubMedPubMedCentral

34.

Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. CMAJ. 1991;145(1):28–34. PMID: 2049694; PMCID: PMC1335560.PubMedPubMedCentral

35.

Campbell P, Baker WL, Bendel SD, White WB. Intravenous hydralazine for blood pressure management in the hospitalized patient: its use is often unjustified. J Am Soc Hypertens. 2011;5(6):473–7. https://doi.org/10.1016/j.jash.2011.07.002.CrossRefPubMedPubMedCentral

36.

Ghani GA, Sung YF, Weinstein MS, Tindall GT, Fleischer AS. Effects of intravenous nitroglycerin on the intracranial pressure and volume pressure response. J Neurosurg. 1983;58(4):562–5. https://doi.org/10.3171/jns.1983.58.4.0562.CrossRefPubMed

37.

Immink RV, van den Born BJ, van Montfrans GA, Kim YS, Hollmann MW, van Lieshout JJ. Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension. 2008;52(2):236–40. https://doi.org/10.1161/HYPERTENSIONAHA.108.110395.CrossRefPubMed

38.

Andrès E, Villalba NL, Zulfiqar AA, Serraj K, Mourot-Cottet R, Gottenberg AJ. State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies. J Clin Med. 2019;8(9):1351. https://doi.org/10.3390/jcm8091351.CrossRefPubMedPubMedCentral

39.

Trimble MA, Sketch MH Jr, Mehta RH. Hemolytic anemia: a rare but potentially serious adverse effect of captopril. Herz. 2007;32(1):62–4. https://doi.org/10.1007/s00059-007-2956-5.CrossRefPubMed

40.

Sica DA, Mannino R. Antihypertensive medications and anemia. J Clin Hypertens (Greenwich). 2007;9(9):723–7. https://doi.org/10.1111/j.1524-6175.2007.06296.x.CrossRefPubMed

41.

Ho IW, Huang CC. Furosemide-induced haemolytic anaemia in an extreme elderly patient. ESC Heart Fail. 2023;10(2):1449–53. https://doi.org/10.1002/ehf2.14299.CrossRefPubMedPubMedCentral

42.

Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anaemia. J Intern Med. 1990;228(6):627–32. https://doi.org/10.1111/j.1365-2796.1990.tb00290.x.CrossRefPubMed

43.

• Carnovale C, Gringeri M, Battini V, Mosini G, Invernizzi E, Mazhar F, et al. Beta-blocker-associated hypoglycaemia: new insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021;87(8):3320–31. https://doi.org/10.1111/bcp.14754. Description: discussion of beta-blocker associated hypoglycemia.CrossRefPubMed

44.

Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. Cardiovasc Diabetol. 2019;18(1):163. https://doi.org/10.1186/s12933-019-0967-1.CrossRefPubMedPubMedCentral

45.

Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS. The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr. 2013;5(1):35. https://doi.org/10.1186/1758-5996-5-35.CrossRefPubMedPubMedCentral

46.

Scheen AJ. Type 2 diabetes and thiazide diuretics. Curr Diab Rep. 2018;18(2):6. https://doi.org/10.1007/s11892-018-0976-6.CrossRefPubMed

47.

Malha L, Mann SJ. Loop diuretics in the treatment of hypertension. Curr Hypertens Rep. 2016;18(4):27. https://doi.org/10.1007/s11906-016-0636-7.CrossRefPubMed

48.

Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112(12):897–903. https://doi.org/10.7326/0003-4819-112-12-897.CrossRefPubMed

49.

Garg MK, Kharb S, Brar KS, Gundgurthi A, Mittal R. Medical management of pheochromocytoma: role of the endocrinologist. Indian J Endocrinol Metab. 2011;15(Suppl 4):S329–36. https://doi.org/10.4103/2230-8210.86976.CrossRefPubMedPubMedCentral

50.

Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gómez MM, et al. β-blockers, cocaine, and the unopposed α-stimulation phenomenon. J Cardiovasc Pharmacol Ther. 2017;22(3):239–49. https://doi.org/10.1177/1074248416681644.CrossRefPubMed

51.

Wilson T, Pitcher I, Bach P. Avoidance of β-blockers in patients who use stimulants is not supported by good evidence. CMAJ. 2022;194(4):E127–8. https://doi.org/10.1503/cmaj.211347.CrossRefPubMedPubMedCentral

52.

Bassotti G, Calcara C, Annese V, Fiorella S, Roselli P, Morelli A. Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers. Dis Colon Rectum. 1998;41(3):377–80. https://doi.org/10.1007/BF02237495.CrossRefPubMed

53.

Ueki T, Nakashima M. Relationship between constipation and medication. J UOEH. 2019;41(2):145–51. https://doi.org/10.7888/juoeh.41.145.CrossRefPubMed

54.

Juurlink DN, Hellings C, Gomes T, Huang A, Paterson JM, Urbach DR, et al. Canadian Drug Safety and Effectiveness Research Network (CDSERN). Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. BMJ Open. 2014;4(7):e005377. https://doi.org/10.1136/bmjopen-2014-005377.CrossRefPubMedPubMedCentral

55.

Phillips W, Piller LB, Williamson JD, Whittle J, Jafri SZ, Ford CE, et al. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. J Clin Hypertens (Greenwich). 2013;15(11):825–32. https://doi.org/10.1111/jch.12180.CrossRefPubMed

56.

Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224. https://doi.org/10.3390/ijms17020224.CrossRefPubMedPubMedCentral

57.

Sharma M, Foge M, Mascarenhas D. A suspected case of hydralazine-induced hepatotoxicity: a case report and review of literature. Am J Case Rep. 2018;19:800–3. https://doi.org/10.12659/AJCR.909279.CrossRefPubMedPubMedCentral

58.

Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: a review. Ochsner J. 2015;15(1):45–51.PubMedPubMedCentral

59.

Kaurich T. Drug-induced acute pancreatitis. Proc (Bayl Univ Med Cent). 2008;21(1):77–81. https://doi.org/10.1080/08998280.2008.11928366.CrossRefPubMed

60.

Johanning RJ, Zaske DE, Tschida SJ, Johnson SV, Hoey LL, Vance-Bryan K. A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning. Pharmacotherapy. 1995;15(6):773–7.CrossRefPubMed

61.

Schulz V, Gross R, Pasch T, Busse J, Loeschcke G. Cyanide toxicity of sodium nitroprusside in therapeutic use with and without sodium thiosulphate. Klin Wochenschr. 1982;60(22):1393–400. https://doi.org/10.1007/BF01716244.CrossRefPubMed

62.

Thomas C, Svehla L, Moffett BS. Sodium-nitroprusside-induced cyanide toxicity in pediatric patients. Expert Opin Drug Saf. 2009;8(5):599–602. https://doi.org/10.1517/14740330903081717.CrossRefPubMed

63.

Rehman HU. Methemoglobinemia. West J Med. 2001;175(3):193–6. https://doi.org/10.1136/ewjm.175.3.193.CrossRefPubMedPubMedCentral

64.

Bojar RM, Rastegar H, Payne DD, Harkness SH, England MR, Stetz JJ, et al. Methemoglobinemia from intravenous nitroglycerin: a word of caution. Ann Thorac Surg. 1987;43(3):332–4. https://doi.org/10.1016/s0003-4975(10)60627-3.CrossRefPubMed

65.

Karachalios GN, Charalabopoulos A, Papalimneou V, Karachalios GN, Charalabopoulos A, Papalimneou V, et al. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract. 2005;59(5):562–70. https://doi.org/10.1111/j.13685031.2005.00520.CrossRefPubMed

66.

Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–50. https://doi.org/10.1016/S0735-6757(96)90147-3.CrossRefPubMed

67.

Anand TV, Wallace BK, Chase HS. Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients. BMC Geriatr. 2021;21(1):648. https://doi.org/10.1186/s12877-021-02594-z.CrossRefPubMedPubMedCentral

68.

Farmer BM, Hayes BD, Rao R, Farrell N, Nelson L. The role of clinical pharmacists in the emergency department. J Med Toxicol. 2018;14(1):114–6. https://doi.org/10.1007/s13181-017-0634-4.CrossRefPubMed

69.

•• American College of Emergency Physicians (ACEP) Clinical pharmacist services in the emergency department. Ann Emerg Med. 2015;66:444–445. https://doi.org/10.1016/j.annemergmed.2015.07.513. Description: ACEP statement regarding the crucial role of ED Clinical Pharmacists.

70.

Dopp JM, Agapitov AV, Sinkey CA, Haynes WG, Phillips BG. Sildenafil increases sympathetically mediated vascular tone in humans. Am J Hypertens. 2013;26(6):762–9. https://doi.org/10.1093/ajh/hpt018.CrossRefPubMedPubMedCentral

71.

Bhogal S, Khraisha O, Al Madani M, Treece J, Baumrucker SJ, Paul TK. Sildenafil for pulmonary arterial hypertension. Am J Ther. 2019;26(4):e520–6. https://doi.org/10.1097/MJT.0000000000000766.CrossRefPubMed

72.

Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33(1):273–82. https://doi.org/10.1016/s0735-1097(98)00656-1.CrossRefPubMed

73.

Sharda SC, Bhatia MS. Comparison of diltiazem and metoprolol for atrial fibrillation with rapid ventricular rate: systematic review and meta-analysis. Indian Heart J. 2022;74(6):494–9. https://doi.org/10.1016/j.ihj.2022.10.195.CrossRefPubMedPubMedCentral

74.

Pea F. β-blockers and diltiazem combination-bear in mind the risk of heart block. JAMA Intern Med. 2017;177(10):1543–4. https://doi.org/10.1001/jamainternmed.2017.4765.CrossRefPubMed

75.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32. https://doi.org/10.1016/j.jacc.2019.01.011.CrossRefPubMed

76.

• Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612. Description: Guidelines for the management of atrial fibrillation, which also make a statement regarding overlapping use of beta-blockers and calcium channel blockers.CrossRefPubMed

77.

Xiao SQ, Ibarra F Jr, Cruz M. Intravenous metoprolol versus diltiazem for rate control in atrial fibrillation. Ann Pharmacother. 2022;56(8):916–21. https://doi.org/10.1177/10600280211056356.CrossRefPubMed

78.

Correia MS, Whitehead E, Cantrell FL, Lasoff DR, Minns AB. A 10-year review of single medication double-dose ingestions in the nationʼs largest poison control system. Clin Toxicol (Phila). 2019;57(1):31–5. https://doi.org/10.1080/15563650.2018.1493205.CrossRefPubMed

79.

Truitt CA, Brooks DE, Dommer P, LoVecchio F. Outcomes of unintentional beta-blocker or calcium channel blocker overdoses: a retrospective review of poison center data. J Med Toxicol. 2012;8(2):135–9. https://doi.org/10.1007/s13181-011-0209-8.CrossRefPubMedPubMedCentral

80.

Alhawassi TM, Krass I, Pont LG. Antihypertensive-related adverse drug reactions among older hospitalized adults. Int J Clin Pharm. 2018;40(2):428–35. https://doi.org/10.1007/s11096-017-0583-7.CrossRefPubMed

81.

O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145.CrossRefPubMed

82.

Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72. https://doi.org/10.1111/jcpt.12059.CrossRefPubMed

83.

• Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2):e21–41. https://doi.org/10.1161/HYP.0000000000000208. Description: Scientific statement from the AHA/ASA on blood pressure management in pregnancy.CrossRefPubMed

84.

Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013 Jul 31;2013(7):CD001449. https://doi.org/10.1002/14651858.CD001449.pub3.

85.

Sinkey RG, Battarbee AN, Bello NA, Ives CW, Oparil S, Tita ATN. Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines. Curr Hypertens Rep. 2020;22(9):66. https://doi.org/10.1007/s11906-020-01082-w.CrossRefPubMedPubMedCentral

86.

Cornette J, Buijs EA, Duvekot JJ, Herzog E, Roos-Hesselink JW, Rizopoulos D, et al. Hemodynamic effects of intravenous nicardipine in severely pre-eclamptic women with a hypertensive crisis. Ultrasound Obstet Gynecol. 2016;47(1):89–95. https://doi.org/10.1002/uog.14836.CrossRefPubMed

87.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–60. https://doi.org/10.1136/bmj.327.7421.955.CrossRefPubMedPubMedCentral

88.

Giannubilo SR, Bezzeccheri V, Cecchi S, Landi B, Battistoni GI, Vitali P, et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet. 2012;286(3):637–42. https://doi.org/10.1007/s00404-012-2371-x.CrossRefPubMed

89.

Yin J, Mei Z, Shi S, Du P, Qin S. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet. 2022;306(6):1891–900. https://doi.org/10.1007/s00404-022-06504-5.CrossRefPubMed

90.

de Bruin R, van Dalen SL, Franx SJ, Ramaswamy VV, Simons SHP, Flint RB, et al. The risk for neonatal hypoglycemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(15):9616. https://doi.org/10.3390/ijerph19159616.CrossRefPubMedPubMedCentral

91.

Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the National Health and Nutrition Examination Survey, 2003 to 2012. Circ Cardiovasc Qual Outcomes. 2017;10(1): e003166. https://doi.org/10.1161/CIRCOUTCOMES.116.003166.CrossRefPubMed

92.

Waldron FA, Benenson I, Jones-Dillon SA, Zinzuwadia SN, Adeboye AM, Eris E, Mbadugha NE, et al. Prevalence and risk factors for hypertensive crisis in a predominantly African American inner-city community. Blood Press. 2019;28(2):114–23. https://doi.org/10.1080/08037051.2019.1568183.CrossRefPubMed

93.

Lu Y, Wang Y, Spatz ES, Onuma O, Nasir K, Rodriguez F, et al. National trends and disparities in hospitalization for acute hypertension among medicare beneficiaries (1999–2019). Circulation. 2021;144(21):1683–93. https://doi.org/10.1161/CIRCULATIONAHA.121.057056.CrossRefPubMed

94.

Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight - reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020;383(9):874–82. https://doi.org/10.1056/NEJMms2004740.CrossRefPubMed

95.

•• Tsai JW, Cerdeña JP, Goedel WC, Asch WS, Grubbs V, Mendu ML, et al. Evaluating the impact and rationale of race-specific estimations of kidney function: estimations from U.S. NHANES, 2015–2018. EClinicalMedicine. 2021;42:101197. https://doi.org/10.1016/j.eclinm.2021.101197. Description: Article evaluating the influence of the renal race-modifier and is credited for changing policy at UNOS transplantation centers.CrossRefPubMedPubMedCentral

Titel: Considering Adverse Effects of Common Antihypertensive Medications in the ED
verfasst von: Charles R. Wira III
Thomas Kearns
Alex Fleming-Nouri
John D. Tyrrell
Christina M. Wira
Ani Aydin
Publikationsdatum: 30.04.2024
Verlag: Springer US
Erschienen in: Current Hypertension Reports
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-024-01304-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Considering Adverse Effects of Common Antihypertensive Medications in the ED

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin